LONDON Nov 26 British pharmaceutical firm BTG
said U.S. regulators had approved its groundbreaking
varicose veins treatment that uses an injectable foam to
dissolve the veins as an alternative to stripping.
Varithena, previously known as Varisolve, has taken more
than a decade to win approval, as the company had to answer
concerns that the active agent in the product polidocanol could
enter the bloodstream.
The company, which had expected a decision from the Food and
Drug Administration (FDA) in the first half of next year, has
previously said global sales of Varithena could reach $500
million a year.
Chief Executive Louise Makin said on Tuesday the product
would set a new standard for the treatment of both the symptoms
and appearance of varicose veins.
"We look forward to the commercial U.S, launch in the second
quarter of 2014, and to continuing to advance our plans to
expand use into other geographies and into non-symptomatic
veins," she said.
Shares in BTG, which also has interventional treatments for
cancer, rose to a more than 11 year high of 521.5 pence after
the announcement on Tuesday. They were trading up 13 percent at
519 pence by 1115 GMT.